A Cost-Utility Analysis Comparing Standard Axillary Lymph Node Dissection with Sentinel Lymph Node Biopsy in Patients with Early Stage Breast Cancer in Thailand  by Songtish, Dolrudee et al.
Avai lable onl ine at www.sc iencedirect .comV A L U E I N H E A L T H R E G I O N A L I S S U E S 3 C ( 2 0 1 4 ) 5 9 – 6 62212-1099/$36.00 –
Published by Elsevie
http://dx.doi.org/10.
Conﬂict of intere
E-mail: dsongtis
* Address correspo
Onkharak, Nakhonnjournal homepage: www.elsevier .com/ locate /vhr iA Cost-Utility Analysis Comparing Standard Axillary Lymph
Node Dissection with Sentinel Lymph Node Biopsy in Patients
with Early Stage Breast Cancer in Thailand
Dolrudee Songtish, MD, Msc1,*, Naiyana Praditsitthikorn, BSc, PhD2,3,
Yot Teerawattananon, MD, PhD2
1Faculty of Medicine, Department of Surgery, Srinakharinwirot University, Nakhonnayok, Thailand; 2Health Intervention and
Technology Assessment Program, Nonthaburi, Thailand; 3Bureau of AIDS TB and STIs, Department of Disease Control, Ministry of
Public Health, Nonthaburi, ThailandA B S T R A C TObjectives: In Thailand, axillary lymph node dissection (ALND) is the
dominant form of treatment for breast cancer, even though the
treatment often leaves patients with some degree of arm morbidity.
Sentinel lymph node biopsy (SNB) is widely accepted globally as a
preferable alternative procedure because of its lower rates of associ-
ated morbidity. This study compared the cost-utility of SNB and ALND
in patients with early stage breast cancer in Thailand. Methods:
A decision tree with a 5-year time horizon was developed. Outcomes
that were relevant to SNB and ALND were included, along with locore-
gional recurrence of cancer and lymphedema scenarios. The model
parameters were derived from a meta-analysis of international clinical
trials and other relevant literature. The resources and cost data were
derived from the medical records of tertiary hospitals. Health utilities
were measured by using the standard gamble technique. A sensitivity
analysis was performed using a set of plausible parameters. Results:
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ayok 26120, Thailand.analysis showed that SNB was more cost-effective than ALND. ICERs
were 275,140 and 470,600 Thailand baht/quality-adjusted life-year
gained from the provider perspective and the societal perspective,
respectively. The most sensitive parameter was the utility score of
patients with early stage breast cancer who had received breast-
conserving therapy with lymphedema; the sensitivity and speciﬁcity
of SNB had no impact on the ICER. Conclusions: The study conﬁrmed
that SNB was an economically viable alternative treatment to ALND. In
developing countries, where resources are limited, nationwide imple-
mentation of SNB warrants widespread support from relevant stake-
holders, including medical personnel and policymakers.
Keywords: axillary lymph node dissection, breast cancer, cost-utility
analysis, sentinel lymph node biopsy.
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Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Over the last 10 years, the incidence of breast cancer in Thailand
has increased signiﬁcantly. The age-standardized rate for breast
cancer has risen from 20.4 per 100,000 in 2003 to 25.6 per 100,000
in 2006. Today, 29,167 cases are diagnosed each year [1], making it
the leading cancer in women in Thailand. Advancements in
cancer care that have occurred over the last 10 years, particularly
the multidisciplinary approach that has resulted from collabora-
tion between surgeons, oncologists, and radiologists, has resulted
in a dramatic improvement in both the survival rate and the
quality of life of patients with breast cancer. Although advanced
adjuvant chemo-radiation plays an important role in cancer care,
surgery is still the main treatment option for local control of
disease. Because the breast lymphatic system is drained through
axillary lymph nodes, axillary lymph node dissection (ALND) has
become a standard treatment for both cancer staging and thecontrolling of local recurrence (LR). Axillary recurrence decreases
the 5-year survival rate of patients with breast cancer by approx-
imately 28% to 40% [2,3]. However, ALND causes arm morbidity in
around 20% of the patients, including symptoms such as frozen
shoulder, armedema, and lymphagitis [4]. Following the introduc-
tion of screening mammograms, the number of stage breast
cancer cases that exhibit axillary metastasis has decreased
signiﬁcantly because of earlier detection [5]. Many studies [6,7]
report that as many as 70% to 80% of patients with early stage
breast cancer show no axillary lymph nodes metastasis. For
patients who show no palpable axillary lymph node, sentinel
lymph node biopsy (SNB) is conducted to identify the ﬁrst drain-
age lymph node, which can prevent the need for ALND. SNB has
been widely accepted worldwide [8] as a comparative procedure to
ALND that can identify early metastasis in patients with early
stage breast cancer who have a tumor smaller than 5 cm and a
clinically nonpalpable axillary lymph node. The procedure hasociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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complications associated with ALND, including long hospital
stays, infection, lymphedema, and frozen shoulder. For instance,
Kell et al. [9] reported a 70% reduction in the rate of lymphedema
and a 75% reduction in the rate of arm numbness for patients who
underwent SNB as opposed to ALND. Veronesi et al. [10] also
found that SNB and ALND resulted in a similar 10-year survival,
LR, and metastasis rates.
Although ALND causes higher levels of morbidity than does
SNB, ALND is still the standard procedure for patients with breast
cancer in Thailand, due to a lack of both trained personnel and
facilities that are necessary to implement SNB nationwide. No
economic evaluation has yet been undertaken in any developing
country setting to compare the cost-effectiveness of ALND and
SNB in terms of cost, treatment outcome, and complications. This
study aimed to address this gap in the data by evaluating the
cost-utility of SNB compared with ALND in patients with early
stage breast cancer in Thailand. The results will help health care
providers and policymakers decide whether to put SNB into
clinical practice throughout the country.Methods
Overview
In Thailand, all patients who are diagnosed with early stage
breast cancer and who have no palpable axillary lymph nodes
undergo either a mastectomy or breast-conserving therapy (BCT);
these surgical treatment options are conducted with either SNB or
ALND, depending on the surgeon’s preference. ALND is far more
common in standard treatment than is SNB, which is currently
performed only in a few university and tertiary hospitals through-
out Thailand. Following SNB or ALNB, chemo-radiation is usually
provided, followed by a 5-year hormonal treatment.
To compare the economic value of SNB with ALND, we
conducted an evaluation using a hypothetical cohort of women
aged 50 years who were diagnosed with early stage breast cancer
and had clinically nonpalpable axillary lymph nodes. We chose to
focus on postmenopausal women aged 50 years because this is
the age at which breast cancer incidence peaks in Thai women
[1]. All costs and outcomes after the ﬁrst year were discounted at
a rate of 3% per annum, as recommended by Thailand’s health
technology assessment guidelines [11].
Design of analysis model
The study was based on a decision analytic model that compared
the cost and utility of ALND with those of SNB in patients with early
stage breast cancer in Thailand from societal and provider perspec-
tives. We generated a decision tree with a 5-year time horizon
(Fig. 1) that covered all relevant outcomes, including lymphedema
and locoregional recurrence rates. All patients were postmeno-
pausal and underwent BCT and either axillary dissection or SNB.
For each procedure, the pathology results may be positive (true
positive, false negative) or negative (true negative, false positive).
Some patients who undergo SNB may later undergo ALND as well,
in cases in which the axillary lymph nodes were found to have
metastasized. There are two main techniques used to identify the
sentinel lymph node in SNB—either a blue dye or a radioactive
substance is injected near to the tumor site. In this study, only the
blue dye technique was included in the analysis because this is the
procedure that is commonly used in the Thai setting. Given the lack
of frozen section data in Thailand, we assumed the frozen section
data from the diagnosis stage of SNB, which is conducted intra-
operationally, to be 100% accurate. Although sensitivity and specif-
icity of SNB were reported from the ﬁnal histopathology
examination, we conducted sensitivity analysis on these twoparameters to minimize these parameters and frozen section uncer-
tainty. Another model assumption was that all SNBs were performed
by experienced surgeons who had passed the “learning curve”
period. After both SNB and ALND, there is a risk that patients may
experience lymphedema in the second and third years after treat-
ment. In the fourth and ﬁfth years, patients experience one of three
possible outcomes—LR, regional recurrence (RR), or no locoregional
recurrence. For those who experience LR, a mastectomy is usually
conducted, either with or without axillary dissection; for those who
experience RR, axillary clearance is usually conducted. In both
recurrence groups, there is a risk that patients might experience
lymphedema after the second surgery. All patients received chemo-
therapy and radiation after treatment, as per standard guidelines.
Final health states represent the outcomes measurement in
most clinical trials, which use the presence of lymphedema, LR,
and RR in the arm (or absence thereof). The distance metastasis
rate in patients with early stage breast cancer is predominantly
dependent on initial staging, which is usually similar in both
arms; therefore, we did not assess this in the analysis.
Model parameters
Clinical parameters were decided on the basis of an extensive
search of the published data. They are summarized in Table 1.
The prevalence of axillary lymph node metastasis in 2-cm tumors
was 31.5%, which increased in-line with tumor size. The sensitivity
and speciﬁcity of SNB were derived from a meta-analysis of six
randomized controlled trials (RCTs) [15–20], which compared SNB
and ALND in patients with early stage breast cancer. The locore-
gional recurrences of SNB were derived from a meta-analysis of ﬁve
RCTs [10,15,22,23], while the recurrence rate for ALND was derived
from a single RCT [24] because no other published data were
available. Because many of the clinical trials that examine lymphe-
dema measurements use many different methods, we used data
only from one RCT (NSABP B-32) to avoid confusion. The NSABP B-32
trial measured the lymphedema rates for both SNB and ALND
patients using the water displacement method, which is recognized
as themost reliablemethod for assessing lymphedema rates [26]. We
analyzed the lymphedema rate as part of our sensitivity analysis.
Utility
Quality-adjusted life-years (QALYs) were derived from the patients’
life-years and utility scores. Utility was measured using the stand-
ard gamble technique in 110 healthy Thai women aged 26 to 60
years because women in these ages can develop breast cancer. All
hypothetical health states were developed on the basis of evidence
from the literature review and expert opinions. Patient-reported
outcomes [28,29] related to health quality of life in patients with
breast cancer were reviewed and modiﬁed so that they were
appropriate for the Thai context. Although the cognitive interview
included questions related to sexual well-being, these responses
were excluded from health state description because they were
deemed irrelevant. Content validation was conducted by three
medical professionals who specialized in caring for patients with
breast cancer and ﬁve patients with breast cancer. The construct
validity was proven by the statistical difference between better
health states and worse health states (such as early stage breast
cancer and recurrence of breast cancer). The six health states were
as follows: 1) early stage breast cancer treated with BCT, with no
recurrence, but with lymphedema; 2) early stage breast cancer
treated with BCT, with no recurrence and without lymphedema; 3)
LR of breast cancer, with lymphedema; 4) LR of breast cancer
without lymphedema; 5) RR of breast cancer, with lymphedema;
and 6) RR of breast cancer without lymphedema. Patients who
experienced LR were treated with a mastectomy with axillary
dissection, whereas those experiencing RR were treated with only
additional axillary dissection. We assumed that the outcomes of
Fig. 1 – Decision tree. ALND, axillary lymph node biopsy; LR, local recurrence; RR regional recurrence; SNB, sentinel lymph
node biopsy.
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Table 1 – Model parameters and data sources.
Parameter Distribution Mean Standard
error
Data source
Probability of axillary metastasis in 2-cm tumors Beta 0.315 0.018 [12–14]
SNB
Sensitivity Beta 0.902 0.017 [15–20]
Speciﬁcity Beta 1.0 0 [15–20]
ALND
Sensitivity Beta 0.304 0.038 [21]
Speciﬁcity Beta 0.988 0.004 [21]
Probability of local recurrence
SNB negative and no metastasis lymph node (true negative) Beta 0.022 0.003 [10,15,22,23]
SNB negative and metastasis lymph node (false negative) Beta 0.019 0.006 [24]
ALND with no metastasis lymph node Beta 0.014 0.006 [10,15,22,23]
ALND with metastasis lymph node Beta 0.036 0.009 [24]
Probability of regional recurrence
SNB negative and no metastasis lymph node (true negative) Beta 0.004 0.002 [10,15,22,23,25]
SNB negative and metastasis lymph node (false negative) Beta 0.009 0.005 [24]
ALND with no metastasis lymph node Beta 0.004 0.001 [10,15,22,23,25]
ALND with metastasis lymph node Beta 0.005 0.003 [24]
Probability of lymphedema
SNB Beta 0.117 0.011 [26]
ALND Beta 0.276 0.013 [26]
Utilities for health states*
Early stage breast cancer status after BCT Beta 0.76 0.04
Early stage breast cancer status after BCT with lymphedema Beta 0.59 0.04
Advanced stage breast cancer with regional recurrence Dirichlet 0.60 0.04
Advanced stage breast cancer with regional recurrence and lymphedema Dirichlet 0.45 0.03
Advanced stage breast cancer with local recurrence Dirichlet 0.61 0.03
Advanced stage breast cancer with local recurrence and lymphedema Dirichlet 0.39 0.03
Cost
Direct medical cost†
First-year cost of SNB Gamma 39,673.80 2,561.30
First-year cost of SNB and ALND Gamma 61,100.37 14,947.61
First-year cost of ALND Gamma 47,737.25 3,794.58
Cost of follow-up of SNB per year Gamma 3,207.51 47.99
Cost of follow-up of SNB and ALND per year Gamma 5,013.62 210.05
Cost of follow-up of ALND per year Gamma 7,954.54 325.54
Operation after local recurrence (2 y) Gamma 44,022.99 44,022.99
Operation after regional recurrence (2 y) Gamma 3,9254.19 3,9254.19
Radiation cost in early stage breast cancer (5 y) Gamma 51,126.51 51,126.51
Chemo-radiation cost for recurring breast cancer (3 y) Gamma 11,7285.6 11,7285.6
Lymphedema care cost (4 y) Gamma 102,084.95 102,084.95
Lymphedema care cost (2 y) Gamma 82,966.29 82,966.29
Direct nonmedical cost
Cost of travel Gamma 142.55 11.60 [27]
Cost of food Gamma 52.51 5.35 [27]
Indirect cost
Cost of productivity loss of patient per day Gamma 80.29 11.34 [27]
Cost of productivity loss of one relative per day Gamma 95.51 35.41 [27]
ALND, axillary lymph node dissection; BCT, breast-conserving therapy; SNB, sentinel lymph node biopsy.
* Data source: Interview (standard gamble technique).
† Data source: Hospital databases
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clinical presentation and would share the same health states given
the similar clinical progression of both procedures but would differ
in the occurrence rate. The utility data are presented in Table 1.Cost
Both the societal and health care provider perspectives were
examined in this analysis. The cost used in the societalperspective was composed of direct medical costs and direct
nonmedical costs, whereas the cost used in the provider per-
spective included only direct medical costs. Direct medical costs
were grouped into three categories—surgical procedures, lym-
phedema care, and radiation and chemotherapy. Direct medical
costs of each procedure comprised operation costs, anesthesia
care costs, hospitalization costs, and related investigation and
medication costs. Lymphedema care costs comprised physiother-
apy care costs and medication costs. Radiation costs comprised
V A L U E I N H E A L T H R E G I O N A L I S S U E S 3 C ( 2 0 1 4 ) 5 9 – 6 6 63radiation therapy costs and medication and investigation costs.
Number of resources used for all cost items and their charge were
derived from the ﬁnancial databases of the university hospital
and the national cancer center. All charges were converted to
costs using the cost to charge ratio reported by Riewpaiboon [27].
Chemotherapy costs were taken from Supakul et al. [31]. Direct
nonmedical costs, which comprised patient expenses for food,
transportation, and costs arising from relative productivity loss
during hospitalization and outpatient visits, were derived from
standard cost lists for health technology assessment [27]. Follow-
up schedules and investigations were in line with those outlined
in international guidelines [32]. Costs of lymphedema comprised
ﬁrst-year procedure costs and follow-up costs per year for 4 or 5
years of radiation treatment. For patients who experienced arm
lymphedema in the second year, additional lymphedema care
costs were calculated for 4 years. If patients had LR or RR, costs
included the operation in the ﬁrst year plus costs associated with
two follow-up years and costs of the second operation and
chemo-radiation. For patients undergoing a second procedure
and who experienced lymphedema, costs included lymphedema
care for 2 years. We excluded the cost of chemotherapy and
hormonal therapy after the ﬁrst treatment because we assumed
that all patients received the same treatment and so the cost
would not affect the results. All costs were adjusted for inﬂation
to the year 2012 by applying the Thai consumer price index [30].
Uncertainty Analysis
A one-way sensitivity analysis was performed on all relevant
parameters, including the prevalence of axillary metastasis,
sensitivity and speciﬁcity of SNB, cost of each procedure, and
utility score. The value of each parameter was tested within a
plausible range of 95% conﬁdence interval (CI) or 10th and 90th
percentile. A threshold analysis was undertaken on relevant
parameters at a willingness-to-pay (WTP) value of 120,000 Thai
baht (THB) per QALY gained, as recommended by the Health
Economic Working Group under the Subcommittee for Develop-
ment of the National List of Essential Drugs. A probabilistic
sensitivity analysis using the Monte-Carlo stimulation with
1000 iterations was undertaken to test the uncertainty of the
model. A gamma distribution was used for cost, while the beta
distribution and the dirichlet distribution was used for probability
and utility parameters, respectively. Because cost of operation
after recurrence, lymphedema care cost, and radiation cost came
from the reimbursement list, values for standard error for these
were not available. We used standard error equal to mean in
sensitivity analysis. A cost-effectiveness acceptability curve was
also presented.Results
The base-case analysis of the cost utility of SNB and ALND in
patients with early stage breast cancer found that SNB cost less
than ALND but resulted in higher QALYs. The incremental cost-
effectiveness ratios (ICERs) of SNB compared with those of ALND
were 275,140 THB/QALY gained from the provider perspective
and 470,600 THB/QALY gained from the societal perspective (see
Table 2).
One-Way Sensitivity Analysis
Our one-way sensitivity analysis (Fig. 2) showed that the utility
score of early stage breast cancer, post-BCT patients with lym-
phedema was the most sensitive parameter, in which a range of
95% CI in the parameter resulted in an ICER range of 145% to
316%. In contrast, the probability of a true positive outcome
(sensitivity) had a minimal effect on ICER for both ALND and SNB.Tumor mass determines the prevalence of axillary metastasis;
given that, a threshold analysis was performed to explore the
effect of the axillary metastasis rate on the value for money of
SNB. The results showed that at a WTP value of 120,000 THB/
QALY gained, SNB was superior to ALND, even when the rate of
axillary metastasis changed from 0% to 85%. The axillary meta-
stasis rate in early stage breast cancer cases, in which the tumor
is smaller than 5 cm, was found to be approximately 49% to 58%
[12–14]. This means that SNB is statistically more cost-effective
than ALND for early stage breast cancer treatment. Given that
some model parameters obtained from international studies are
generally more accurate than parameters garnered from clinical
practice, the sensitivity and speciﬁcity of SNB were also tested.
The results from the one-way sensitivity analysis showed that
both parameters were less sensitive to ICER change and that SNB
was still more cost-effective even when the sensitivity and
speciﬁcity of the test decreased. The lymphedema rate after
ALND was tested because the severity of lymphedema in post-
ALND patients can vary widely, and many patients with a mild
form of lymphedema may not require treatment. We found that
ALND was the more cost-effective treatment option, when fewer
than 10% of the patients developed lymphedema; however, this
was not veriﬁable in the clinical setting, in which more than 10%
of the patients who had ALND develop lymphedema. Moreover,
direct medical cost applied in this study did not include the cost
that occurred during the learning curve of SNB; however, in one-
way sensitivity analysis, ICER showed minimal change when the
direct medical cost of SNB in the ﬁrst year varied between 10th
and 90th percentile.
Probabilistic Sensitivity Analysis
The probabilistic sensitivity analysis showed that SNB is more
cost-effective than ALND for all WTP values (Fig. 3). At a WTP
value of 120,000 THB, the probability of SNB being cost-effective
was 77.5% while the probability of ALND being cost-effective was
22.5%.Discussion
Our cost-utility analysis was based on a 5-year decision tree
model that compared the cost-effectiveness of ALND with SNB
treatments for patients with early stage breast cancer in Thailand
from both the provider and societal perspectives. SNB was found
to be cost saving from both perspectives, giving an ICER of
275,140 THB/QALY gained from the provider perspective and
470,600 THB/QALY gained from the societal perspective. At
Thailand’s ceiling threshold of 120,000 THB/QALY gained, the
probability that SNB would be cost-effective in patients with early
stage breast cancer was found to be 77.5%. Some model param-
eters were derived from international studies, in which breast
cancer tends to be diagnosed at an earlier stage than in Thailand,
and so tumors tend to be smaller and the risk of axillary meta-
stasis is correspondingly lower. Despite this, our threshold
analysis still conﬁrmed SNB to be the most cost-effective option,
despite the signiﬁcantly high risk of axillary metastasis (85%). In
clinical practice, however, SNB was not recommended for
patients with a tumor larger than 5 cm because of its high
false-negative rate with tumors of that size.
In Thailand, most patients with breast cancer undergo a
mastectomy, in contrast to most international contexts that have
been studied, in which BCT is the most common surgical treat-
ment. Many studies [33,34] have shown that the outcomes of
mastectomy are comparable with those of BCT in terms of LR and
survival rate. However, because of criteria and follow-up period
limitations in previous studies, no deﬁnitive evidence has yet
Table 2 – Cost-effectiveness of SNB and ALND in provider and societal perspective.
Treatment QALYs Cost (THB) ICER
Provider Societal Provider Societal
ALND* 3.385 152,212 215,473
SNB* 3.431 139,552 193,820 275,140 470,600
ALND, axillary lymph node dissection; ICER, incremental cost-effectiveness ratio; QALYs, quality-adjusted life years; SNB, sentinel lymph node
biopsy; THB, Thai baht.
* Excluding cost of ﬁrst chemotherapy and hormonal treatment.
F
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each procedure. However, the one-way sensitivity analysis that
was conducted as part of this study on the probability of
developing lymphedema revealed a range of 95% CI. The results
showed a minimal change in ICER as a result of developing
lymphedema, and SNB was still considered more cost-effective.
The one-way sensitivity analysis of the sensitivity and speciﬁcity
of SNB demonstrated that SNB was still more cost-effective
than ALND.
In 2012, Verry et al. [38] compared the cost-effectiveness of
SNB with that of ALND from the provider perspective using a
Markov model over a 20-year period. The study parameters were
mainly garnered from the Sentinel Node versus Axillary Clear-
ance trial [18], and the utility was derived from Kanis et al. [39].
The study showed that SNB was marginally more cost-effective
than ALND and indicated several sensitive parameters that
affected the outcomes. The researchers highlighted the need for
more reliable information on the speciﬁcity of SNB and the risk of
axillary recurrence after SNB; we did not identify this need in our
study. Although no relevant clinical trials have yet been con-
ducted in Thailand from which we could derive our parameters,
we ensured that the parameters were appropriate for the Thaiig. 2 – The percentage change in ICER compared with the mean IC
ained. ALND, axillary lymph node dissection; BCT, breast-conse
ALY, quality-adjusted life year; SNB, sentinel lymph node biopscontext by deriving the utility from healthy Thai women and
testing sensitive parameters through a sensitivity analysis. The
most sensitive parameter that we identiﬁed in our analysis was
the utility of early stage breast cancer post-BCT patients with
lymphedema. Although SNB had the additional cost of patho-
logical examination, there were studies [40,41], which compared
direct medical costs between SNB and ALND in the early post-
operative period, that found that SNB was cost saving and
hospital stay cost was the most signiﬁcant parameter. In our
study, the duration of hospital stay between both groups was not
much different because the patients were discharged early and
had follow-up at the outpatient clinic. Because most breast
cancer treatments are undertaken in outpatient clinics, we
included direct nonmedical costs and examined the data from
both the provider and societal perspectives. The ICER from the
societal perspective was found to be nearly twice that from the
provider perspective, and the cost of travel was one of the most
sensitive parameters. After conducting the probabilistic sensitiv-
ity analysis with 1000 iterations in a range of probable values of
total cost, health outcomes, and ICERs, the results showed that
the probability of SNB being more cost-effective than ALND at
different WTP values was more than 70%.ER for each parameter. Mean ICER ¼ 470,602.22 THB/QALY
rving therapy; ICER, incremental cost-effectiveness ratio;
y; THB, Thai baht.
Fig. 3 – Cost-effectiveness acceptability curve. ALND, axillary lymph node dissection; QALY, quality-adjusted life-year; SNB,
sentinel lymph node biopsy.
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data to interpret the cost-utility between SNB and ALND over a
lifetime. Our model aimed to evaluate the efﬁcacy of SNB in
reducing lymphedema while also giving similar LR and RR rates
to ALND. Recurrence almost always occurs within 5 years after
treatment, and so this model is deemed to be a good model for
predicting recurrence rates. We did not include survival as an
outcome because this fell outside the timescale of our model. Our
assumption was in line with the data from Veronesi et al. [10], the
longest follow-up clinical trial, results of which showed that
mortality in early stage breast cancer was strongly predicated
by initial staging and treatment and that after 10-year follow up
there was no statistically signiﬁcant difference in the mortality
rate between SNB and ALND groups.Conclusions
Our study demonstrated that SNB gives patients with early stage
breast cancer a better quality of life and is a more cost-effective
option than ALND. The results are generalizable to other
Southeast-Asian countries because these countries share broadly
similar living costs, cultural norms, and lifestyles to those
examined in our study. Moreover, our ﬁndings make a clear case
for clinicians and policymakers to provide SNB treatment nation-
wide to improve the standard of care for Thai patients with breast
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